PECONDLE® (picankibart injection) has received approval from China's National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy. PECONDLE® is the world's first IL-23p19 antibody whose...
Hence then, the article about china s first domestic il 23p19 monoclonal antibody innovent s pecondle picankibart injection received nmpa approval was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval )
Also on site :
- One person in critical condition following two-vehicle collision on SR-126 at Boosey Road
- Kentucky congressman announces death of longtime staffer, campaign manager
- Man injured after jumping from upper floors of Grand Mosque in Makkah